Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Order Online! Now! Get your $50 coupon for online order. 
Get 50% off discount for CGT related product lines!
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one! Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers ! Time Limited Offer: Welcome Gift for New Customers !
5e5 of anti-MSLN CAR-293 cells were stained with 100 μL of 3 μg/mL of AF488-Labeled Human Mesothelin (296-580), His Tag (Cat. No. MSN-HA2H9) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). AF488 signal was used to evaluate the binding activity (QC tested).
Anti-human MSLN mAb (chimeric mouse-human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface, can bind RFP Fusion Human Mesothelin (296-580), His Tag (Cat. No. MSN-HR2P4) with an affinity constant of 0.304 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Anti-human MSLN MAb (chimeric mouse-human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface, can bind GFP Fusion Human Mesothelin (296-580), His Tag (Cat. No. MSN-HG2P4) with an affinity constant of 0.542 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| RNA-Meso-CIR-T | RNA-Meso-CIR-T | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Mesothelioma | Details |
| Anti-mesothelin CAR-T (Pregene) | Clinical | Pregene (Shenzhen) Biotechnology Co Ltd | Hydrothorax | Details | |
| Anti-mesothelin CAR-NK cell therapy(Guojianchengnuo) | ALF-101 | Phase 1 Clinical | Carcinoma, Ovarian Epithelial | Details | |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| Anetumab ravtansine | BAY-94-9343; BAY-94-9343-SPDB-DM4; Anti-mesothelin antibody-drug conjugate BAY 94-9343 | Phase 2 Clinical | Bayer AG, Morphosys Ag | Ovarian Neoplasms; Solitary Fibrous Tumor, Pleural; Cystadenocarcinoma, Serous; Neoplasms; Pancreatic Neoplasms; Mesothelioma; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Endometrioid | Details |
| Gavocabtagene autoleucel | TC-210 | Phase 2 Clinical | Tcr2 Therapeutics Inc | Ovarian Neoplasms; Mesothelioma; Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| LD013 CAR T-cell therapy (Nanjing Landun Biotechnology) | LD013; LD-013 | Phase 1 Clinical | Nanjing Landun Biotechnology Co Ltd | Solid tumours; Ovarian Neoplasms | Details |
| Anti-MESO CAR-T cell(Ruijin Hospital) | Phase 1 Clinical | Ruijin Hospital | Solid tumours; Neoplasms | Details | |
| SynKIR-110 | SynKIR-meso; SynKIR™-110 | Phase 1 Clinical | Verismo Therapeutics Inc | Ovarian Neoplasms; Mesothelioma; Cholangiocarcinoma | Details |
| HPN-536 | HPN-536 | Phase 2 Clinical | Harpoon Therapeutics | Neoplasms | Details |
| anti-MESO CAR-T cells (Zhejiang University) | Phase 2 Clinical | Zhejiang University, Hrain Biotechnology Co Ltd | Ovarian Neoplasms | Details | |
| iCasp9M28z | iCasp9M28z | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Pleural Diseases; Mesothelioma; Breast Neoplasms; Lung Neoplasms; Neoplasm Metastasis | Details |
| RC-88 | RC-88 | Phase 2 Clinical | RemeGen Co Ltd | Solid tumours; Neoplasms | Details |
| Anti-mesothelin CAR T cell therapy (UTC Therapeutics Inc) | Phase 1 Clinical | UTC Therapeutics Inc | Solid tumours | Details | |
| Inezetamab | AMG-994 | Phase 1 Clinical | Amgen Inc | Solid tumours; Neoplasms | Details |
| anti-mesothelin thorium-227 labeled antibody chelator conjugate | BAY-2287411 | Phase 1 Clinical | Bayer AG | Ovarian Neoplasms; Mesothelioma; Carcinoma, Pancreatic Ductal; Adenocarcinoma | Details |
| KD-021 | KD-021 | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Neoplasms | Details |
| RD-138 | RD-138 | Phase 1 Clinical | Multiple Myeloma | Details | |
| αPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd) | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Ovarian Neoplasms; Colorectal Neoplasms | Details | |
| RD-133 | RD133 | Phase 1 Clinical | Solid tumours | Details | |
| CD40 ligand expressing MSLN-CAR T cells | Phase 2 Clinical | Pla General Hospital | Solid tumours | Details | |
| AB-1015 | AB-1015 | Phase 1 Clinical | Arsenal Biosciences Inc | Ovarian Neoplasms; Carcinoma, Ovarian Epithelial | Details |
| Autologous Mesothelin-specific TCR-T Cell Therapy (Lonza Walkersville) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal | Details | |
| CART-meso | CART-meso | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Ovarian Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Adenocarcinoma of Lung; Mesothelioma; Breast Neoplasms; Fallopian Tube Neoplasms | Details |
| LMB-100 | LMB-100; RG-7787; RO-6927005 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Carcinoma; Neoplasms, Mesothelial; Neoplasms; Adenocarcinoma of Lung; Pancreatic Neoplasms; Mesothelioma; Cholangiocarcinoma; Pleural Effusion, Malignant; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| PM-3006 | PM-3006 | Phase 1 Clinical | Biotheus Inc | Details |
This web search service is supported by Google Inc.
A-Z
